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Abstract
Background: Over the past decade, gene expression microarray studies have greatly expanded our knowledge of
genetic mechanisms of human diseases. Meta-analysis of substantial amounts of accumulated data, by integrating
valuable information from multiple studies, is becoming more important in microarray research. However,
collecting data of special interest from public microarray repositories often present major practical problems.
Moreover, including low-quality data may significantly reduce meta-analysis efficiency.
Results: M
2DB is a human curated microarray database designed for easy querying, based on clinical information
and for interactive retrieval of either raw or uniformly pre-processed data, along with a set of quality-control
metrics. The database contains more than 10,000 previously published Affymetrix GeneChip arrays, performed using
human clinical specimens. M
2DB allows online querying according to a flexible combination of five clinical
annotations describing disease state and sampling location. These annotations were manually curated by
controlled vocabularies, based on information obtained from GEO, ArrayExpress, and published papers. For array-
based assessment control, the online query provides sets of QC metrics, generated using three available QC
algorithms. Arrays with poor data quality can easily be excluded from the query interface. The query provides
values from two algorithms for gene-based filtering, and raw data and three kinds of pre-processed data for
downloading.
Conclusion: M
2DB utilizes a user-friendly interface for QC parameters, sample clinical annotations, and data formats
to help users obtain clinical metadata. This database provides a lower entry threshold and an integrated process of
meta-analysis. We hope that this research will promote further evolution of microarray meta-analysis.
Background
Rapid accumulation of vast amounts of microarray data
in public databases like Gene Expression Omnibus
(GEO) [1] and ArrayExpress [2] over the past few years
has now made it possible to retrieve, integrate, and
compare microarray results from many datasets [3,4].
Research has used meta-analysis of microarray results
by integrating data from multiple independent studies to
successfully identify novel prognosis and diagnosis sig-
natures for cancer and other diseases [5-8]. Microarray
meta-analysis involves a systematic search for suitable
datasets in retrieval, filtering, re-processing, integration,
and analysis. The entire process is complex, laborious,
and time-consuming [4]. In an effort to disentangle the
complexity of microarray meta-analysis studies, Rama-
samy et al. addressed several key issues [4]. However, as
noted by these authors, obstacles and challenges remain.
First, identifying suitable studies for meta-analysis is a
time-consuming process because experimental informa-
tion is often stored in a free-text format in a data
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adopted the Minimum Information about a Microarray
Experiment (MIAME) [9] standard, consistent formats
and terminologies for annotating experiments and sam-
ples are not specified. The completeness and accuracy
of information largely depend on the meticulousness of
authors, and this issue constitutes a major challenge for
microarray meta-analysis.
Second, re-processing raw data is of great importance
for integrating data from multiple datasets [4,10,11], but
raw data are not always available. As cautioned by
Ochsner et al., fewer than 50% of all microarray studies
published in the twenty top-ranked journals during 2007
resulted in depositing datasets into microarray data
repositories [12]. Only some of the deposited datasets
provide raw intensity data. Taking the Affymetrix HG-
U133A platform as an example, only 44% of the samples
submitted to the GEO contain raw data files [10].
Third, using pre-processed data by different algo-
rithms will introduce variations into the results of meta-
analysis [4,13]. Different datasets typically use different
normalization methods, and therefore data downloaded
from different sets of experiments are unlikely to be
directly comparable. These data are unsuitable for meta-
analysis and may produce non-combinable results [4,14].
As suggested by Ramasamy et al., even for studies con-
ducted using the same microarray platform, the raw
data should be uniformly pre-processed and normalized
using the same algorithm to remove systematic biases
for all tested datasets [4].
Fourth, several investigators have suggested consider-
ing data quality within the context of microarray meta-
analysis [4,11,13]. Recent studies conducted by the
MicroArray Quality Control (MAQC) consortium and
others have demonstrated that good laboratory profi-
ciency and the resulting improved data quality signifi-
cantly enhance inter-laboratory and inter-platform
reproducibility [15-17]. Moreover, including potential
outliers in meta-analysis reduces normalization effi-
ciency, especially when using small datasets for pre-pro-
cessing [11]. Therefore, it is important to identify and
eliminate poor-quality data before the pre-processing
step [4,10]. However, quality assessment does not
accompany microarray data retrieved from public repo-
sitories. Therefore, extra efforts are needed to determine
the quality of retrieved microarray data.
A number of databases or web servers have recently
been developed to tackle these problems. For example,
Celsius [18] is a data warehouse that collects Affymetrix
CEL files and seven kinds of pre-processed metadata.
CleanEX [19] re-annotates microarray datasets with
MeSH terms to facilitate the data-retrieval process.
MaRe [20] and GEOmetadb [21] provide tools to facili-
tate the search and retrieval of data from GEO or
ArrayExpress. The M
3D [14] has collected Affymetrix
m i c r o a r r a yd a t aa n dp r o v i d e smanually curated experi-
mental conditions, and uniformly normalized microarray
data on three microbial species for download. Oncomine
[22] has extensively collected, annotated, and standar-
dized human cancer arrays for various platforms. Gene-
Sapiens [23] re-annotates the samples, applies quantile
normalization, and offers gene-based scatterplot/correla-
tions between pairs of genes across tissues in its website.
However, depending on the aim and scope of these stu-
dies, the problems listed above have only been partially
resolved.
This study develops M
2DB, an expert curated data-
base, to solve microarray data retrieval, annotation, pre-
processing, and quality-assessment problems. M
2DB
contains more than 10,000 previously published Affyme-
trix array data, re-annotated with controlled vocabul-
aries from ontologies (most from NCI Thesaurus),
according to available clinical information. Samples of
interest can be easily queried, based on five clinical
annotations: “Disease State,”“ Disease State Suppl.,”“ Dis-
ease Location,”“ Organism Part,” and “Organism Part
Subtype.” Raw data were retrieved from HG-U133A and
HG-U133 plus 2.0 and were uniformly pre-processed
using Affymetrix Microarray Suite 5 (MAS5) [24],
robust multi-chip average (RMA) [25], and GC-robust
multi-chip average (GCRMA) [26]. Quality-control
assessment reports, for array-base filtering, generated
using SimpleAffy [27], Mahalanobis Distance Quality
Control (MDQC) [28], and Parametric MultiVariate
Outlier labeling (PMVO) [29], packages of Bioconductor
[30], were provided for all samples. Arrays with low-
quality measurements can be easily excluded from the
M
2DB web query interface. MAS5call and labeling effi-
ciency values (LEVs) [31] are supplied for gene-based
filtering for further analysis. The many features offered
by M
2DB efficiently facilitate the search and retrieval
process, as well as ensuring the reliability of human clin-
ical microarray metadata. In summary, M
2DB provides
human curated annotations, raw data, uniformly prepro-
cessed data, and sets of QC metrics, and significantly
improves the quality and comparability of microarray
metadata generated by different laboratories.
Construction and content
As illustrated in Figure 1, datasets for human studies
were collected from public repositories. After the com-
pletion of sample annotation, quality assessment, and
data pre-processing, the data were stored in the M
2DB
server.
Dataset collection and pre-processing
Raw intensity data (CEL files) generated using Affyme-
trix HG-U133A and HG-U133 plus 2.0 platforms were
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formed using samples other than human clinical speci-
mens, such as cell lines, primary cells, and transformed
cells, were excluded. In addition, datasets without links
to publications were also excluded except Expression
Project for Oncology (expO) (GSE2109). A total of 69%
of published arrays which contain raw data were per-
formed by human clinical samples. The other 31% of
arrays were hybridized to cell lines, primary culture
cells, transformed cells, etc. About 8% of clinical arrays
were uploaded to repositories more than once. We
removed the redundant arrays according to the genera-
tion date of CEL files. Eventually, M
2DB contains more
than 10,000 Affymetrix GeneChip arrays from 192
experiments in ArrayExpress (158 out of 192
experiments also belong to GEO). All microarray raw
data were pre-processed using three different algo-
rithms: MAS5, RMA, and GCRMA as implemented in
the Bioconductor packages. RMA and GCRMA pro-
cessed data on a multi-array basis; therefore all arrays of
t h es a m ep l a t f o r mw e r eu n i formly pre-processed to
reduce variance.
The Affymetrix microarray system is recognized as
naturally suited for meta-analysis [32] and was used as
t h eo n l ym i c r o a r r a ys y s t e mi nM
2DB, based on several
factors. First, the Affymetrix platform provides a consis-
tent and reliable system with a high level of reproduci-
bility [10,14,33]. Second, mapping probes to genes using
datasets on different platforms is a complex process [4].
Using datasets originatin gf r o mt h es a m ep l a t f o r m
Figure 1 Schematic process diagram of M
2DB. Affymetrix GeneChip HG-U133A and HG-U133 Plus 2.0 arrays with CEL files are downloaded
from GEO and ArrayExpress. Then, raw data was pre-processed using MAS5, RMA, and GCRMA. All arrays were annotated into five annotations
via manual curation. Array quality assessed by SimpleAffy, PMVO, and MDQC packages in Bioconductor. MAS5call and labeling efficiency values
(LEVs) are supplied for gene-based filtering for further analysis. Finally, all information was stored in M
2DB.
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design enables between-chip comparison without a com-
mon reference for all arrays [14]. Fourth, many pre-pro-
cessing, normalization, and QC algorithms are readily
available for the Affymetrix platform. Fifth, Affymetrix is
the most popular commercial microarray platform, and
a very large number of Affymetrix microarray datasets
have been deposited into public microarray repositories
[34]. On the other hand, there are several obstacles in
integrating data from different platforms (including
Affymetrix and non-Affymetrix), such as various data
processing methods, complex probe-to-gene relation-
ships, and difficulty in comparing results [17]. Moreover,
the strategy of M
2DB is providing relative “pure” data to
reduce the variance of data processing in meta-analysis.
For these reasons, we excluded non-Affymetrix plat-
forms from M
2DB.
Sample annotation
To ensure annotation consistency and make the retrieval
process more efficient, clinical information for each
sample was manually curated, based on data obtained
from GEO, ArrayExpress, and published papers. As
shown in Figure 1, each sample was re-annotated with
five clinical characteristics: Disease State, Disease State
Suppl., Disease Location, Organism Part, and Organism
Part Subtype. Organism Part and Organism Part Sub-
type describe the sample location. Disease State, Disease
State Suppl., and Disease Location describe the physio-
logical state and disease information of individuals.
“Organism Part” describes the anatomical location of a
sample, such as tissue, organ, blood, or body part.
“Organism Part Subtype” is an additional annotation for
“Organism Part,” containing information such as cell
types or specified regions in an organ (for example,
Organism Part: heart; Organism Part Subtype: left ven-
tricular). “Disease State” simply classifies samples into
four categories: Normal, Cancer or Tumor, Disease, and
Abnormality. “Normal” means specimens were collected
from apparently healthy individuals without signs of dis-
ease. “Cancer or Tumor” specifies that the sample was
collected from a cancerous tissue. “Disease” describes
that the sample was collected from a diseased site or
one under the influence of disease. “Abnormality”
means the specimen was collected from an apparently
healthy individual who was under the influence of che-
mical agents, such as alcohol, or was classified as having
a metabolic syndrome, such as abnormal glucose toler-
ance. These annotations are designed to help users find
the required samples quickly and easily. “Disease State
Suppl.” contains supplementary information for “Disease
State,” for example, the disease name for a “Disease”
specimen or the reasons why a sample is annotated as
“Abnormality.”“ Disease Location” specifies the
anatomical location of a disease or the primary site of a
cancer. In most cases, clinical samples were obtained
from the diseased organ, and therefore the organism
part is the same as the disease location. However, when
samples were obtained from a tissue other than the dis-
eased organ, the organism part is different from the dis-
ease location.
T h e s ef i v ec h a r a c t e r i s t i cs were derived from MGED
ontology, but some were modified for easier querying.
In order to obtain an accurate clinical annotation from
the free-text descriptions in GEO, ArrayExpress, and
related papers, terms used in annotations are controlled
vocabularies from existing ontologies (besides the terms
of Disease State Suppl. in Abnormality of Disease State).
This research manually extracted relative information
from the free-text description of each sample, then iden-
tified accurate terms and unified the synonyms via the
Bioportal [35], Ontology Lookup Service (OLS) [36] and
NCI Enterprise Vocabulary Services (EVS). To fit in
with the authors’ original intention of the adopted
papers and provide an accurate clinical annotation from
the free-text description, this work adopted several
ontologies instead of a single ontology. About 90% of
terms are from NCI thesaurus, and 10% from other
ontologies such as the Foundation Model of Anatomy
(FMA) and the Systematized Nomenclature of Medi-
cine-Clinical Terms (SNOMED-CT). [See Additional file
1 and 2 for each term and its source]. Terms for each
sample were identified by a team of six biologists and
medical doctors. Therefore, we annotate all samples
with these five characteristics. Approximately 5% of clin-
ical arrays were excluded due to incomplete information
for sample annotation. Other clinical information, such
as sex, age, or ethnicity, was not included in M
2DB for
query because it is frequently not available.
Data quality control
For array-based quality control, Affymetrix recommends
using a set of QC factors to describe hybridization per-
formance and array quality. M
2DB provides QC metrics
generated by three R packages, SimpleAffy, MDQC, and
PMVO. SimpleAffy provides a set of QC factors devel-
oped based on the Affymetrix QC report. PMVO and
M D Q Ca r em u l t i v a r i a t ea p p r o a c h e st h a tu s e dt oe v a l u -
ate the quality of an array. MDQC examines the “Maha-
lanobis distance” of its quality attributes from those of
other arrays, while PMVO uses parametric multivariate
outlier testing using a multivariate Gaussian model.
Five QC factors are included on the query interface
for custom definition: scale factor, average background,
the 3’/5’ intensity ratio of GAPDH, the 3’/5’ intensity
ratio of beta-actin, and the proportion of probes called
present (percentpresent) as provided by SimpleAffy. The
default cutoff values were selected according to the
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et al. [10]: scale factor < 3 fold differences; the 3’/5’
intensity ratio of GAPDH < 1.25; the 3’/5’ intensity ratio
of beta-actin < 3; percentpresent > 10%. These factors
are also used for multivariate testing in MDQC and
PMVO. Three percentiles, 90, 95, and 99, are provided
as selection criteria for respective distributions on the
query interface for these two methods.
For gene-based filtering, the database provides MAS5-
call and LEVs. The MAS5 algorithm supplies the
MAS5call, which annotates whether the gene is
expressed in specimen. LEV accesses the effect of RNA-
labeling efficiency and RNA quality. Research has pro-
ven that filtering out genes with highly variable LEV
improves the comparability between different labora-
tories and the homogeneity of gene expression profiles
within the same class of specimens [31].
Utility
Query interface
A ss h o w ni nF i g u r e2 ,t h eM
2DB web query interface
consists of two parts. Part I provides “sample type,”
“platform,” and “quality control” criteria for selection.
“Sample type” indicates whether the RNA samples for
hybridization are “individual,” from a single individual,
or “pooled,” from multiple individuals. Only two plat-
forms, HU133A and HU133 plus 2.0, are supported in
M
2DB, and users can choose either one or both. The
“quality control” option provides SimpleAffy, PMVO,
and MDQC QC factors. For SimpleAffy, users can
choose the default value or define a customized value
for each QC factor. For PMVO and MDQC, three distri-
bution percentiles are offered in their respective algo-
rithms as QC thresholds.
Part II provides a “flexible combination selection” of five
clinical annotations for samples which passed the criteria
in Part I. Users can define from one to five annotations for
query. The types of annotation and their quantities can be
visualized in real time according to users’ combined selec-
tions. This combination selection helps users quickly
reduce the number of items submitted for query. For
example, there are more than 250 items in “Disease State
Suppl.” By applying the combination of “Cancer or
Tumor” in “Disease State” and “uterine cervix” in “Disease
Location”, the number of items submitted for selection in
“Disease State Suppl.” reduces to less than five. On the
other hand, users can define different combinations
according to their demand. For example, users can select
222 tumors collected from the lung by applying the com-
bination of “Cancer or Tumor” in “Disease State” and
“lung” in “Organism Part”. When adding the criterion:
“lung” in “Disease Location”, there are only 215/222 sam-
ples classified into lung cancer. In this case, 7/222 samples
are classified into lung metastasis.
Experiment/Sample information
The experiment information table contains simple
descriptions of experiments and hyperlinks to the GEO,
ArrayExpress, and PubMed web sites to obtain more
complete information. The sample information table
contains complete clinical annotations and QC factors
from SimpleAffy, PMVO, and MDQC for each sample.
Moreover, the database provides an “additional selection
box” for each sample to enable making further selec-
tions. Users have an additional option to decide whether
a sample is suitable for further analysis according to the
complete information in the table.
Data format and submission
After confirming the selected samples, users can define
which type of data to download. M
2DB offers four data
types: one is raw data (CEL files), and the other three
are normalized data (RMA, GCRMA, and MAS5). The
database also provides MAS5call and LEVs as gene-base
filtering. After entering an email address, the user sub-
mits the job to the server. The user receives two email
alerts. One is a confirmation email informing the user
that the job has been successfully submitted and is
being processed. The other email with a download link
is sent when the job is completed.
Discussion
To quickly and easily query samples, annotation cate-
gories adopt a flat list instead of a tree structure. For
example, only two annotations, the Organism Part and
the Organism Part Subtype, are used to describe the
sample location in anatomic position. This choice is
motivated by the increased complexity of the ontological
tree structure in our web design. Additionally, the
Organism Part is only used to describe the sample loca-
tion in MGED ontology. In M
2DB, we created the
Organism Part Subtype to assist users to define the sam-
ple location. For example, T lymphocyte samples can be
derived from blood, bone marrow, or umbilical cord
blood in the database. The two annotations, Organism
Part and Organism Part Subtype, can be more accurate,
efficient, and less complicated to define the sample loca-
tion. According to our annotation categories, users can
easily and quickly find samples defined in the selection
via our web query interface. It provides instantaneous
visualization and selective combination (up to five cri-
teria) of the various quantities and types of items
selected.
Detailed descriptions of experimental parameters and
sample clinical information are necessary to make the
metadata fully interpretable. However, complete descrip-
tions are frequently not available or only partially avail-
able in either microarray repositories or published
papers. Accordingly, in M
2DB, the authors supplied
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according to free-text descriptions of the collected
experiments. If researchers require further clinical infor-
mation for advanced analysis, support from the authors
of original published papers will be necessary. The
authors therefore urge public microarray repositories to
request microarray researchers for more detailed infor-
mation, such as sex, age, disease-free survival...etc. This
would greatly encourage microarray meta-analysis across
different experiments.
The uniform pre-processing eliminates the technical
variance of data transformation, such as background
Figure 2 Web query interface of M
2DB.M
2DB Web interface consists of three parts: 1). Sample selection according to sets of QC metrics and
manually curated annotation, 2). The display of Experiment/Sample information, where the “additional selection box” enables to make further
selection, and 3). Data Format and Submission panel.
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Gagarin et al. demonstrated that two different summari-
zations of the same data may produce differential
expression gene (DEG) lists that are only 30% concor-
dant [37]. However, laboratory-to-laboratory variation is
hard to eliminate, even if adopting the same data trans-
formation process. Yang et al. carried out a study in
which a common set of RNA sample was performed five
times in four different laboratories using Affymetrix
GeneChip arrays. Significant discrepancies exist in
intensity profiles and DEG lists across laboratories [38],
resulting in intrinsic variance for meta-analysis studies.
There are several statistical algorithms developed to
relieve this problem [39-42]. Microarray analysis web-
sites, for example ArrayMining [43], also provide cross
studies/platforms normalization. Another way to allevi-
ate laboratory-to-laborato r yv a r i a n c ei sb yr e m o v i n g
poor quality arrays. Several studies have emphasized the
importance of QC for integrative microarray studies
[4,10,11,13]. Owzar et al. proved that removing the out-
lier arrays could relieve batch effect [11]. Ramasamy et
al. suggested array quality control as one of the key
issues of microarray meta-analysis studies [4].
Housekeeping genes have been used for normalization
in gene expression analysis, such as quantitative RT-
PCR, northern blotting, and gene expression microarray
[44-47]. Furthermore, the expression variation of house-
keeping genes between arrays has been used to evaluate
the effectiveness of normalization methods [48]. We had
used the expression variation of housekeeping genes to
examine the effect of array quality control. HU133A
arrays performed by normal skeleton muscle in M
2DB
were selected for the analysis. After submitting these
clinical annotations for query, forty-nine samples from
seven different datasets were identified by M
2DB. The
expression variation of each housekeeping gene is pre-
sented as C.V. of intensity as shown in the Additional
file 3. In general, the expression variation of the house-
keeping genes was reduced when one of the array-based
QC methods was applied. These results indicate that
applying anyone of the array-based QC methods effec-
tively excludes arrays with poor quality and reduces
laboratory- to-laboratory variance in the microarray
meta-analysis.
M
2DB can be used by researchers to collect metadata
for the following purposes: 1) Searching for biomarkers
of prognosis or disease [49-51]. 2) Using metadata to
validate their own results. For example, according to
gene expression pattern derived from 28 patients,
Vachani et al. identified a panel of ten genes to accu-
rately distinguish two tumor types; this set of marker
genes was validated by 134 individuals collected from
four independent previously published Affymetrix data-
sets [52]. 3) Integrating with their own datasets to
increase sample size. For example, Lu et al. applied a
meta-analysis of datasets including their own samples
and five experimental data collected from other micro-
array studies [53]. Furthermore, for clinical studies, col-
lecting normal samples is a major difficulty. M
2DB
includes more than 1,800 normal samples from healthy
individuals without diseases, abnormalities, or treat-
ments according to the descriptions of the experiments.
These data from normal samples can help researchers
discover and address the differences between normal
and diseased (abnormal) specimens by cross-comparing
different datasets.
Many public microarray web servers have provided
analysis tools such as differential expression, clustering,
and supervised classification. Thus, M
2DB does not put
extra effort into constructing online analysis tools. Users
can directly upload the M
2DB’s results to those analysis
web servers, for example Expression Profiler [54],
GEPAS [55], EzArray [56], or ArrayMining [43]. Users
with advanced knowledge and skills in data analysis may
find it is more feasible to download raw data files (CEL
files) and QC metrics to local computers or to transfer
them to public analysis web servers, such as WebAr-
rayDB [57], CARMAweb [58], Expression Profiler [54],
GEPAS [55], and EzArray [56], which allow user upload
CEL files, for more advanced meta-analysis.
MIAME 2.0 now requests authors to deposit their raw
data files in public microarray depositories. This policy
will greatly help in data integration and meta-analysis.
M
2DB is updated periodically to incorporate new experi-
ments which provide raw intensity data. Newly incorpo-
rated microarray data will be re-annotated. It took six
researchers about one month to curate ~20,000 arrays
(including clinical and non-clinical arrays) and to anno-
tate clinical arrays into five clinical characteristics.
Finally, we selected 10,202 arrays into M
2DB. In the
future, when expending the dataset, the needed time
will be proportional to the amount of new arrays. In
addition, the entire set of raw data will be uniformly re-
processed using normalization as well as QC algorithms
when adding new chips into M
2DB.
Conclusions
This research develops M
2DB to facilitate the search
and retrieval process, as well as to ensure the reliability
of human clinical microarray metadata. Providing raw
data, uniformly pre-processed data, and several sets of
QC metrics, M
2DB can be used to significantly improve
the quality and comparability of microarray metadata
generated by different laboratories. The manually
curated annotations with the “flexible combination
selection” relieve time-consuming searching and help
researchers easily find the clinical expression data they
need. M
2DB provides a lower entry threshold and an
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database will promote further evolution of microarray
meta-analysis.
Availability and requirements
The web-application is freely accessible at http://metadb.
bmes.nthu.edu.tw/m2db/.
Additional material
Additional file 1: Summary list of sample location. The excel file
containing the summary list of sample location for 10202 samples of
M
2DB.
Additional file 2: Summary list of disease information. The excel file
containing the summary list of disease information for 10202 samples of
M
2DB.
Additional file 3: The intensity C.V. of 14 housekeeping genes in
normal skeleton muscles. The expression variation of 14 housekeeping
genes in normal skeleton muscles.
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